How digital health companies are capitalizing on the GLP-1 boom
Publishing timestamp: 2024-05-25 09:00:01
Summary
Analysts predict the anti-obesity medication industry could reach $100 billion by the end of the decade. Companies like Calibrate, Ro, and WeightWatchers are capitalizing on the growing demand for GLP-1 medications. Patients are seeing success with these programs, but challenges like medication shortages and insurance coverage remain.
Sentiment: MIXED
Tickers: NOVO.B-DK, HIMS, GS, LLY, NVO, TDOC, WW,
Keywords: eli lilly and co, breaking news: technology, novo nordisk a/s, technology, internet, goldman sachs group inc, hims & hers health inc, health care industry, ww international inc, business news, teladoc health inc,
Source: https://www.cnbc.com/2024/05/25/digital-health-companies-are-launching-programs-around-glp-1s-.html